Diagnosis and management of complement mediated thrombotic microangiopathies

Blood Reviews

Volumn 28, Issue 2, 2014, Pages 67-74

  Cataland, Spero R ^a   Wu, Haifeng M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAMTS13; Atypical hemolytic uremic syndrome; Complement activation; Diagnosis; Thrombotic thrombocytopenic purpura

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT FACTOR H; CREATININE; ECULIZUMAB; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

COMPLEMENT ACTIVATION; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; END STAGE RENAL DISEASE; GENE MUTATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEUROLOGIC DISEASE; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE;

ADAMTS13; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DIAGNOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT SYSTEM PROTEINS; CREATININE; DIAGNOSIS, DIFFERENTIAL; ENZYME ACTIVATION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME;

EID: 84896078812     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.01.003     Document Type: Article

References (58)

1. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
2. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
3. Zipfel P.F., Heinen S., Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010, 19:372-378.
4. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9:729-740.
5. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325:398-403.
6. George J.N. How I, treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000, 96:1223-1229.
7. Ariceta G., Besbas N., Johnson S., Karpman D., Landau D., Licht C., et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24:687-696.
8. Loirat C., Sonsino E., Hinglais N., Jais J.P., Landais P., Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988, 2:279-285.
9. Rizzoni G., Claris-Appiani A., Edefonti A., Facchin P., Franchini F., Gusmano R., et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988, 112:284-290.
10. Michael M., Elliott E.J., Craig J.C., Ridley G., Hodson E.M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009, 53:259-272.
11. Noris M., Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 2009, 5:186-188.
12. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
13. Carr R., Cataland S.R. Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 2013, 92:845-846.
14. Salem G., Flynn J.M., Cataland S.R. Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 2013, 92:557-558.
15. Fakhouri F., Delmas Y., Provot F., Barbet C., Karras A., Makdassi R., et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014, 63:40-48.
16. Remuzzi G., Galbusera M., Noris M., Canciani M.T., Daina E., Bresin E., et al. Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002, 100:778-785.
17. Cataland S.R., Wu H.M. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. Eur J Intern Med 2013, 24:486-491.
18. Bresin E., Daina E., Noris M., Castelletti F., Stefanov R., Hill P., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.
19. Loirat C., Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008, 12:619-629.
20. Lhotta K., Janecke A.R., Scheiring J., Petzlberger B., Giner T., Fally V., et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009, 4:1356-1362.
21. Zheng X.L., Kaufman R.M., Goodnough L.T., Sadler J.E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004, 103:4043-4049.
22. Coppo P., Bengoufa D., Veyradier A., Wolf M., Bussel A., Millot G.A., et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004, 83:233-244.
23. Kremer Hovinga J.A., Vesely S.K., Terrell D.R., Lammle B., George J.N. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2009.
24. Jang M.J., Chong S.Y., Kim I.H., Kim J.H., Jung C.W., Kim J.Y., et al. Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 2011, 93:163-169.
25. Matsumoto M., Bennett C.L., Isonishi A., Qureshi Z., Hori Y., Hayakawa M., et al. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 2012, 7:e33029.
26. Coppo P., Schwarzinger M., Buffet M., Wynckel A., Clabault K., Presne C., et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010, 5:e10208.
27. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A., Macher M.A., Niaudet P., Guest G., et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007, 18:2392-2400.
28. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
29. Gulleroglu K., Fidan K., Hancer V.S., Bayrakci U., Baskin E., Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013, 28:827-830.
30. Ohanian M., Cable C., Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 2011, 3:45-50.
31. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood.115:1500-11; quiz 662.
32. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584.
33. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
34. Veyradier A., Obert B., Houllier A., Meyer D., Girma J.P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001, 98:1765-1772.
35. Tsai H.M. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003, 14:1072-1081.
36. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003, 1:632-634.
37. Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica.
38. Chapin J., Weksler B., Magro C., Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012, 157:772-774.
39. Chen F.M., Ou-Yang F., Yang S.F., Tsai E.M., Hou M.F. P53 codon 72 polymorphism in Taiwanese breast cancer patients. Kaohsiung J Med Sci 2013, 29:259-264.
40. Zuber J., Fakhouri F., Roumenina L.T., Loirat C., Fremeaux-Bacchi V. French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657.
41. Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood.115:1500-11; quiz 662.
42. Raife T., Atkinson B., Montgomery R., Vesely S., Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004, 44:146-150.
43. Bentley M.J., Wilson A.R., Rodgers G.M. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. Vox Sang 2013, 105:313-318.
44. Cataland S.R., Yang S., Wu H.M. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012, 157:501-503.
45. Jin M., Casper T.C., Cataland S.R., Kennedy M.S., Lin S., Li Y.J., et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008, 141:651-658.
46. Carreras L., Romero R., Requesens C., Oliver A.J., Carrera M., Clavo M., et al. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3, B7 haplotype. JAMA 1981, 245:602-604.
47. Stuhlinger W., Kourilsky O., Kanfer A., Sraer J.D. Letter: haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet 1974, 2:788-789.
48. Noris M., Ruggenenti P., Perna A., Orisio S., Caprioli J., Skerka C., et al. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J Am Soc Nephrol 1999, 10:281-293.
49. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodriguez de Cordoba S., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475-486.
50. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
51. Fremeaux-Bacchi V., Fakhouri F., Garnier A., Bienaime F., Dragon-Durey M.A., Ngo S., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
52. Harboe M., Thorgersen E.B., Mollnes T.E. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2011, 63:976-987.
53. Reti M., Farkas P., Csuka D., Razso K., Schlammadinger A., Udvardy M.L., et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012, 10:791-798.
54. Wu T.C., Yang S., Haven S., Holers V.M., Lundberg A.S., Wu H., et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013, 11:1925-1927.
55. Howard M.A., Williams L.A., Terrell D.R., Duvall D., Vesely S.K., George J.N. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006, 46:154-156.
56. Bouts A., Monnens L., Davin J.C., Struijk G., Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011, 26:1919-1920.
57. Hillmen P., Muus P., Roth A., Elebute M.O., Risitano A.M., Schrezenmeier H., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013, 162:62-73.
58. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.